The expression level of MIIP is decreased in many types of cancer, including glioma, lung cancer, colon cancer, endometrial carcinoma and pancreatic cancer, and correlates with advanced clinical stage and shorter survival time of the patients [17–22]. Here, MIIP is linked to central nervous system cancer.